← Back to Search

Monoclonal Antibodies

Open-Label for Asthma (RITE Trial)

Phase 2
Waitlist Available
Led By Michael Wechsler, MD
Research Sponsored by National Jewish Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

RITE Trial Summary

Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.

Eligible Conditions
  • Asthma

RITE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Document the safety of reslizumab therapy in patients with EGPA
Secondary outcome measures
Demonstrate the steroid sparing effect of reslizumab therapy by titrating corticosteroid dosage

Side effects data

From 2014 Phase 3 trial • 489 Patients • NCT01287039
38%
Asthma
16%
Upper respiratory tract infection
11%
Nasopharyngitis
9%
Sinusitis
8%
Headache
7%
Influenza
5%
Oropharyngeal pain
5%
Bronchitis
5%
Urinary tract infection
5%
Back pain
5%
Rhinitis allergic
4%
Cough
4%
Pharyngitis
2%
Dizziness
1%
Pneumonia
1%
Chest pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Reslizumab 3.0 mg/kg

RITE Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-LabelExperimental Treatment1 Intervention
all subjects will receive the study medication- reslizumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reslizumab
FDA approved

Find a Location

Who is running the clinical trial?

Teva Pharmaceuticals USAIndustry Sponsor
230 Previous Clinical Trials
188,198 Total Patients Enrolled
10 Trials studying Asthma
135,248 Patients Enrolled for Asthma
National Jewish HealthLead Sponsor
140 Previous Clinical Trials
316,226 Total Patients Enrolled
23 Trials studying Asthma
17,774 Patients Enrolled for Asthma
Michael Wechsler, MDPrincipal InvestigatorNational Jewish Health
4 Previous Clinical Trials
199 Total Patients Enrolled
2 Trials studying Asthma
49 Patients Enrolled for Asthma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Michael Wechsler 2017. "Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02947945.
All > Granulomatosis With Polyangiitis
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top